Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Leukemia, Myeloid, Acute 97Precursor Cell Lymphoblastic Leukemia-Lymphoma 61Myelodysplastic Syndromes 52Recurrence 37Leukemia, Lymphocytic, Chronic, B-Cell 37Multiple Myeloma 36Lymphoma, Non-Hodgkin 35Lymphoma 34Lymphoma, B-Cell 29Hematologic Neoplasms 28Lymphoma, Follicular 24Lymphoma, Large B-Cell, Diffuse 23Melanoma 22Lymphoma, Mantle-Cell 22Leukemia 22Lymphoma, B-Cell, Marginal Zone 20Myeloproliferative Disorders 19Leukemia, Myelogenous, Chronic, BCR-ABL Positive 19Leukemia, Biphenotypic, Acute 18Hodgkin Disease 18Ovarian Neoplasms 17Burkitt Lymphoma 17Pancreatic Neoplasms 16Neoplasms 13Neoplasm Metastasis 12Leukemia, Myelomonocytic, Chronic 12Colorectal Neoplasms 11Anemia, Refractory, with Excess of Blasts 11Stomach Neoplasms 10Carcinoma, Non-Small-Cell Lung 10

Interventions

pembrolizumab 1fludarabine 1Radiotherapy, Intensity-Modulated 1Losartan 1LY3300054 1Gemcitabine 1Cyclophosphamide 1Cisplatin 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Camurati-Engelmann Syndrome × fludarabine × 1 year × Clear all
NCT02065362 2026-01-29

TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC

Baylor College of Medicine

Phase 1 Active not recruiting
14 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Camurati-Engelmann Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡